Home >  Investors Relations >  CryoLife Announces Release Date & Teleconference Call Details for 2017 Third Quarter Financial Results

CryoLife Completes Acquisition of JOTEC

December 1, 2017 at 5:04 PM EST

ATLANTA, Dec. 1, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair. 

Cryolife logo. (PRNewsFoto/CryoLife, Inc.) (PRNewsFoto/CRYOLIFE_ INC_) (PRNewsFoto/CRYOLIFE, INC.)

About CryoLife

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable living tissues used in cardiac and vascular surgical procedures.  CryoLife markets and sells a highly competitive product portfolio focused on treating aortic disease in more than 80 countries worldwide.  For additional information about CryoLife, visit our website, www.cryolife.com.

Contacts:




CryoLife        

D. Ashley Lee                                                 

Executive Vice President, Chief Financial Officer and
Chief Operating Officer
Phone: 770-419-3355

The Ruth Group

Zack Kubow

646-536-7020

zkubow@theruthgroup.com

View original content with multimedia:http://www.prnewswire.com/news-releases/cryolife-completes-acquisition-of-jotec-300565402.html

SOURCE CryoLife, Inc.